Related Experiment Video
Updated: Jul 6, 2026
05:50
Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
Published on: September 26, 2025
Structure-based virtual screening against SARS-3CL(pro) to identify novel non-peptidic hits
Prasenjit Mukherjee1, Prashant Desai, Larry Ross
1Department of Medicinal Chemistry, School of Pharmacy, University of Mississippi, Faser 417, University, MS 38677, USA.
Bioorganic & Medicinal Chemistry
|March 18, 2008
Summary
Researchers identified novel inhibitors for SARS-3CL(pro), a key enzyme in severe acute respiratory syndrome coronavirus (SARS-CoV). This discovery aids in developing new antiviral therapies against this infectious disease.
Area of Science:
- Biochemistry
- Drug Discovery
- Virology
Background:
- Severe acute respiratory syndrome (SARS) is a highly infectious disease caused by SARS-associated coronavirus (SARS-CoV).
- The SARS-3CL(pro) enzyme is a viral cysteine protease essential for SARS-CoV replication, making it a crucial therapeutic target.
- Elucidated crystal structures of SARS-3CL(pro) enable structure-based drug design for inhibitor discovery.
Purpose of the Study:
- To develop a robust and predictive molecular docking protocol for identifying SARS-3CL(pro) inhibitors.
- To perform structure-based virtual screening of a compound library against SARS-3CL(pro).
- To identify and biologically evaluate novel inhibitors of the SARS-3CL(pro) viral protease.
Main Methods:
- Utilized the Gold docking program for extensive docking studies against the SARS-3CL(pro) crystal structure.
- Developed and validated a docking protocol for virtual screening.
- Conducted structure-based virtual screening of the Asinex Platinum collection against the validated protocol.
- Performed biological evaluation of selected compounds to identify protease inhibitors.
Main Results:
- A robust and predictive docking protocol was successfully developed and validated.
- Structure-based virtual screening identified potential inhibitor candidates from the Asinex Platinum collection.
- Biological evaluation confirmed the inhibitory activity of selected compounds against SARS-3CL(pro).
Conclusions:
- The study successfully established a validated docking protocol for SARS-3CL(pro) inhibitor discovery.
- Novel inhibitors of the SARS-3CL(pro) viral protease were identified through structure-based virtual screening.
- These findings contribute to the development of rational drug design strategies against SARS-CoV.
